[go: up one dir, main page]

CO6400226A2 - Micrólido anti-inflamatorio - Google Patents

Micrólido anti-inflamatorio

Info

Publication number
CO6400226A2
CO6400226A2 CO11095916A CO11095916A CO6400226A2 CO 6400226 A2 CO6400226 A2 CO 6400226A2 CO 11095916 A CO11095916 A CO 11095916A CO 11095916 A CO11095916 A CO 11095916A CO 6400226 A2 CO6400226 A2 CO 6400226A2
Authority
CO
Colombia
Prior art keywords
inflammatory
microlid
compound
diethylaminoethanyl
homoerythromycin
Prior art date
Application number
CO11095916A
Other languages
English (en)
Inventor
Caroline Jane Day
Julien Bruno Douillet
Darko Filic
Leanda Jane Kindon
Goran Kragol
Zorica Marusic-Istuk
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6400226(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6400226A2 publication Critical patent/CO6400226A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

El compuesto 3'-N-desmetil-4"-O-(2-dietilaminoetanoil)-6-O-metil-9a-aza-9a-homoeritromicina A, que tiene la Fórmula (I):o una sal del mismo, composiciones que comprenden el compuesto, su uso en el tratamiento de enfermedades inflamatorias dominadas por neutrófilos, y métodos para su preparación.
CO11095916A 2009-01-30 2011-07-29 Micrólido anti-inflamatorio CO6400226A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14860909P 2009-01-30 2009-01-30

Publications (1)

Publication Number Publication Date
CO6400226A2 true CO6400226A2 (es) 2012-03-15

Family

ID=41698466

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11095916A CO6400226A2 (es) 2009-01-30 2011-07-29 Micrólido anti-inflamatorio

Country Status (23)

Country Link
US (1) US8227428B2 (es)
EP (1) EP2384333B1 (es)
JP (1) JP5437394B2 (es)
KR (1) KR20110099791A (es)
CN (1) CN102378763A (es)
AR (1) AR075340A1 (es)
AU (1) AU2010209732B2 (es)
BR (1) BRPI1006114A2 (es)
CA (1) CA2748847A1 (es)
CL (1) CL2011001829A1 (es)
CO (1) CO6400226A2 (es)
DO (1) DOP2011000242A (es)
EA (1) EA201101139A1 (es)
ES (1) ES2412059T3 (es)
IL (1) IL213871A0 (es)
MA (1) MA32997B1 (es)
MX (1) MX2011008074A (es)
PE (1) PE20120220A1 (es)
SG (1) SG172782A1 (es)
TW (1) TW201038277A (es)
UY (1) UY32408A (es)
WO (1) WO2010086349A1 (es)
ZA (1) ZA201104653B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006215315B2 (en) 2005-01-13 2012-02-16 Glaxo Group Limited Macrolides with anti-inflammatory activity
US8227428B2 (en) 2009-01-30 2012-07-24 Glaxo Group Limited Anti-infammatory macrolide
WO2011116312A1 (en) * 2010-03-19 2011-09-22 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
WO2011131749A1 (en) * 2010-04-23 2011-10-27 Glaxo Group Limited New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
KR20190095372A (ko) * 2017-01-13 2019-08-14 토비시 파마슈티칼 컴패니 리미티드 호중구 활성화 조절제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525051A (en) 1894-08-28 Adjustable chair
US3725385A (en) 1970-11-02 1973-04-03 Abbott Lab Process for the demethylation of 3-amino macrolides
EP0126344A2 (en) 1983-05-20 1984-11-28 Abbott Laboratories Tripeptide esters of therapeutic agents
PT87417B (pt) * 1987-05-06 1992-08-31 Adir Processo para a preparacao de novos compostos macrolidos
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
HRP980189B1 (en) 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
AU772283B2 (en) * 1999-05-18 2004-04-22 Pfizer Products Inc. Novel crystalline forms of a macrolide antibiotic
HRP20010301A2 (en) 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1521764A2 (en) 2002-07-08 2005-04-13 PLIVA-ISTRAZIVACKI INSTITUT d.o.o. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
ITMI20021726A1 (it) 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
GB0310986D0 (en) 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
DE602006004555D1 (de) 2005-01-13 2009-02-12 Glaxosmithkline Zagreb Decladinosyl-macrolide mit entzündungshemmender wirkung
AU2006215315B2 (en) * 2005-01-13 2012-02-16 Glaxo Group Limited Macrolides with anti-inflammatory activity
ATE523519T1 (de) 2005-01-14 2011-09-15 Glaxo Group Ltd Makrolidverbindungen mit biotin und fotoaffinitätsgruppe zur identifizierung eines makrolid-targets
US8227428B2 (en) 2009-01-30 2012-07-24 Glaxo Group Limited Anti-infammatory macrolide

Also Published As

Publication number Publication date
EA201101139A1 (ru) 2012-03-30
EP2384333A1 (en) 2011-11-09
IL213871A0 (en) 2011-07-31
AU2010209732B2 (en) 2012-12-20
BRPI1006114A2 (pt) 2018-02-06
WO2010086349A1 (en) 2010-08-05
KR20110099791A (ko) 2011-09-08
JP5437394B2 (ja) 2014-03-12
TW201038277A (en) 2010-11-01
MX2011008074A (es) 2011-08-17
AR075340A1 (es) 2011-03-23
UY32408A (es) 2010-07-30
CN102378763A (zh) 2012-03-14
MA32997B1 (fr) 2012-01-02
DOP2011000242A (es) 2011-09-15
US8227428B2 (en) 2012-07-24
ZA201104653B (en) 2012-02-29
CL2011001829A1 (es) 2011-10-14
JP2012516304A (ja) 2012-07-19
AU2010209732A1 (en) 2011-07-21
SG172782A1 (en) 2011-08-29
EP2384333B1 (en) 2013-04-17
PE20120220A1 (es) 2012-04-04
ES2412059T3 (es) 2013-07-10
US20100197623A1 (en) 2010-08-05
CA2748847A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
AR077629A1 (es) Mimetico de smac
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
GT201400111A (es) Triazolopiridinas sustituidas
UY32062A (es) Inhibidores de beta-secretasa
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CR20150075A (es) Nuevo derivado de cumarina que tiene efecto antitumoral
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
CR20120264A (es) Compuestos
ECSP10010216A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
CL2011002849A1 (es) Composicion anti-inflamatoria que comprende microorganismos sometidos a tratamiento a por lo menos 71,5 grados celsius durante por lo menos 1 segundo; uso de una composicion para tratar o prevenir padecimientos inflamatorios; metodos para proporcionar los microorganismos.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
AR110128A2 (es) Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
CU20120171A7 (es) Triazolopiridinas sustituidas
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
GT200500360A (es) Compuestos organicos
CO6400226A2 (es) Micrólido anti-inflamatorio
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
BR112015013071A2 (pt) solução de trombina e seus métodos de uso

Legal Events

Date Code Title Description
FA Application withdrawn